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Abstract
Background: This study aimed to determine the societal economic burden and health-related quality of life (HRQOL)
of cystic fibrosis (CF) patients in the UK.
Methods: A bottom-up cost-of-illness, cross-sectional, retrospective analysis of 74 patients was conducted aiming to
estimate the economic impact of CF. Data on demographic characteristics, health resource utilisation, informal care,
productivity losses and HRQOL were collected from questionnaires completed by patients or their caregivers. HRQOL
was measured with the EuroQol 5-domain (EQ-5D) instrument.
Results: Using unit costs for 2012 we found that the average annual cost for a CF patient was €48,603, with
direct health care costs amounting to €20,854 (42.9 % of total costs), direct non-health care costs being €21,528 (44.3 %)
and indirect costs attributable to productivity losses being €6,222 (12.8 %). On average, the largest expenditures by far
were accounted for by informal care (44.1 %), followed by medications (14.5 %), acute hospitalisations (13.9 %), early
retirement (9.1 %) and outpatient and primary health care visits (7.9 %). Sharp differences existed depending on whether
CF patients were in need of caregiver help (€76,271 versus €26,335). In adult CF patients, mean EQ-5D index scores were
0.64 (0.93 in the general population) and mean EQ-5D visual analogue scale scores were 62.23 (86.84 in the general
population); among caregivers, these scores were 0.836 and 80.85, respectively.
Discussion: Our analysis highlights the importance of the economic and quality of life consequences of CF from a societal
perspective. The results highlight that beyond conventional costs such as acute hospitalisations, medication and outpatient
and primary care visits, indirect costs related to informal care and early retirement, have significant societal implications.
Similarly, our analysis showed that the average EQ-5D index score of adult CF patients was significantly lower than in the
general population, an indication that a methodological bias may exist in using the latter in economic analyses.
Conclusion: CF poses a significant cost burden on UK society, with non-health care and indirect costs representing 57 %
of total average costs, and HRQOL being considerably lower than in the general population.
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Background
Cystic fibrosis (CF) is one of the most prevalent, fatal,
inherited rare disorders among people of Caucasian des-
cent. The European prevalence ranges between 1/8,000
and 1/10,000 individuals [1]. Data from the UK CF neo-
natal screening NHS newborn blood spot-screening
programme, suggest that 1 in 2,500 babies are born with
the disease [2]. The natural course of the disease in-
volves a gradual and progressive deterioration in lung
function due to the deranged chloride transport, leading
to thick and viscous secretions not only in the lung but
also in pancreas, liver, intestine and reproductive tract [3].
Complications due to chronic colonisation by bacteria,
lead to destruction of lung architecture and respiratory
failure and are the most common causes of death among
CF patients [4].
A dramatic improvement in survival among CF patients
has been observed in recent years [5] and, as a result, CF is
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no longer a major mortality cause among children [6, 7].
Despite its low disease prevalence, CF exerts a potentially
important economic impact on health care resources, and
other social costs [8, 9] and has significant impact on
patients’ health-related quality of life (HRQOL) [10–12].
The issue of total costs related to the treatment of CF
and the HRQOL for CF patients is poorly understood.
Although a number of recent studies have measured in-
dependently the economic and HRQOL impact on CF
patients [8–16], a comprehensive study in the UK that
examines all cost dimensions (direct medical, direct
non-medical and indirect costs) and links cost with
HRQOL is missing [17].
In this study we report and analyse CF patient-level
primary data from the UK collected under the auspices
of the BURQOL-RD initiative [18]. The study objectives
are twofold: first, to estimate the societal costs of CF by
accounting for all direct health, direct non-health care
and indirect costs, and, second, to assess the HRQOL of
patients with CF.
Methods
Research design and sample
This was a bottom-up, retrospective, cross-sectional study
of non-institutionalised patients diagnosed with CF, re-
ceiving outpatient care. Because of the lack of a publicly
available, NHS-based CF registry in the UK, a convenience
sample of patients was recruited from the Cystic Fibrosis
Trust (CFT) that holds its own anonymised register of pa-
tients. The survey was anonymous and patients were con-
tacted by the Trust. A CF diagnosis, non-institutionalised
status and membership of CFT determined patient eligi-
bility. Questionnaire responses received by the research
team had no identification information (name, address/
postcode, e-mail or telephone). All patients and caregivers
were informed about the study objective, data confidenti-
ality and were asked to indicate their understanding of the
study conditions and agreement to participate. The study
protocol was submitted to the London School of Econom-
ics (LSE) Research Ethics Committee and received an
exemption.
Information and variables of interest
Following the identification of the patient sample, CFT
sent questionnaires electronically and by post to eligible
patients at the end of February 2013. The questionnaire
comprised two parts, the first identifying costs and the
second including HRQOL. The data collection was car-
ried out between end-February and end-May 2013, with
reminders sent at the end of April and May. Demo-
graphic, clinical and resource use data were collected
from CF patients and their caregivers. The questionnaire
was detailed enough to reduce either exaggeration or
underestimation.
Following receipt of completed questionnaires, patients
were divided into two groups: first, high severity or dis-
ability, needing caregiver assistance in order to perform
basic (dressing, hygiene, eating, etc.) or instrumental (meal
preparation, shopping, laundry) daily activities; and, sec-
ond, low severity or disability, if they did not need such
assistance.
Costing methodology
We used the prevalence approach to estimate resource
use and, subsequently, costs from a societal perspective.
Disease prevalence takes into account all direct health
care resources used for prevention, treatment and re-
habilitation, other non-health care resources used (for-
mal and informal care), and indirect costs (productivity
loss) within a given year (in a population or in a sample
of patients) as a consequence of the illness considered.
Prevalence-based cost-of-illness analysis has the advan-
tage of incorporating measurements of total annual
health care expenditure, which is particularly relevant
for chronic conditions such as CF requiring long-term
treatment. In this context, a bottom-up costing approach
was used to estimate total and average annual costs.
Data on resource utilisation were collected for each
patient and, where appropriate, caregiver. To estimate
resource utilisation, the questionnaire solicited informa-
tion covering the 6-month period prior to the study
(12 months for hospital admissions). Data for the pre-
ceding 6 months were extrapolated to the entire year.
We considered 6 months to be an appropriate recall
period [19]. Patients and caregivers were asked about re-
ductions in working time (temporary and permanent
sick leave or early retirement), and these data were used
to calculate productivity losses. Non-professional care-
givers were also asked about informal care time. A list of
basic domestic activities (e.g. dressing, bathing, feeding,
etc.) and other non-domestic activities (e.g. travelling,
shopping, socialising, etc.) was provided, and carers had
to specify the approximate daily or weekly time they
spent on these activities.
Direct medical costs were derived from health care
utilisation. The cost of resources used by patients was
calculated based on the relevant unit costs and the aver-
age utilisation per patient in the sample. Information
about the number of hospital admissions, the number of
emergency visits and data for the volume of outpatient
care (rehabilitation, medical tests and examinations,
visits to health professionals and home medical care)
were obtained from the questionnaires.
Unit costs were obtained mostly from the UK payment
by results database [20]; additional publicly available
resources were used to fill in any remaining data gaps
[21, 22]. Unit costs were then multiplied by the respect-
ive resource quantities to derive the annual cost per
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patient, using 2012 as the reference year. In a similar way,
resource utilisation information relating to consumption
of prescription drugs and medical support devices was
obtained from the questionnaires. When no information
concerning the number of units per pack was available,
we assumed the largest dispensing pack for prescription
drugs. Prescription drug unit costs were obtained from
the National Drug Tariff database [23] and the British Na-
tional Formulary [24], whereas unit costs for medical sup-
port devices were obtained from major electronic
commerce websites.
Direct non-health care costs were the result of aggre-
gating three items: non-health care transportation, social
care services (formal care) and caregiver’s time (informal
care, provided by non-professional caregivers, who are
often relatives, but could also be friends or neighbours
and who are not paid for the care provided). Informal
care concerned the time spent helping the patient with
their basic activities of daily living (ADL), and the time
spent helping with necessary instrumental activities of
daily living (IADL). The approach used to value care
hours was the proxy good method, which values time as
an output and values the care provided by the informal
caregiver considering that if they did not provide these
services, their presence would have to be substituted by
a professional caregiver who could provide them [25].
Information on formal (paid) care provided by profes-
sional caregivers and other social services was obtained
from the questionnaires and is included under the social
services category.
Indirect costs were obtained from physical units (days
of sick leave and early retirement) converted into monet-
ary units based on the human capital approach [26],
using worker gross average earnings from the Annual
Survey of Hours and Earnings [27] conducted by the Of-
fice for National Statistics to proxy productivity losses.
Patient and caregiver outcomes
Patient and caregiver outcomes were obtained via the
EQ-5D-5 L questionnaire [28], the Barthel Index [29]
and the Zarit Burden Interview [30]. The EQ-5D-5 L is
a generic instrument of HRQOL, commonly used in
economic evaluations and routinely included in health
technology assessments. Its five dimensions (mobility,
self-care, everyday activities, pain/discomfort and anx-
iety/depression), enable a total of 245 possible health
states to be defined, taking values from 0 (death) to 1
(perfect health). The second part of the EQ-5D consists
of a vertical 20-cm, 0–100 Visual Analogue Scale (VAS),
where 0 represents the worst and 100 represents the best
imaginable health states. Respondents mark a point on
the scale to reflect their overall health on the day of the
interview [28]. Evaluations of these health states have
been reported for the general population [31].
The Barthel Index is widely used to assess physical dis-
ability and measures the ability of a person to perform
ten basic ADL, obtaining a quantitative estimate of the
subject’s degree of dependence. Total possible scores for
the UK range between 0 and 20, with lower scores indi-
cating increased disability [29].
Finally, the Zarit Burden Interview (22-item version)
measures the subjective burden among caregivers. Each
item is a statement to which the caregiver is asked to
respond using a 5-point scale, with options ranging from
0 (never) to 4 (nearly always). The total score ranges from
0 to 88, with scores under 21 corresponding to little or no
burden and scores over 61 to severe burden [30].
Results
Of the 234 questionnaires sent, 131 questionnaires
(56 %) were returned from CF patients. Of these, 57
questionnaires were excluded because the information
they contained was deemed to be insufficient or inad-
equate. Therefore, the valid sample totalled 74 patient
questionnaires.
Table 1 summarises the main characteristics of the
sample. Patients were equally divided between adult and
non-adult (37 patients each) and average patient age was
18 years; 52.7 % of patients were male and 44.6 % (33
patients) had a caregiver, whose average age was 37.3 years.
The total average time spent on informal caregiving,
assuming at least one caregiver, was 74.8 hours per week,
(3,900 hours per year).
Estimated average annual cost per patient in 2012 was
€48,603, and the median was €34,883 (Table 2). Direct
non-health care cost was the largest component (44.3 %
of the total average cost per patient), followed by direct
health care costs (42.9 %) and productivity loss (12.8 %)
(Fig. 1). The most important categories of health care
costs were medications, (33.8 % of health care and 14.5 %
of total costs), followed by acute hospitalizations (32.4 %
of health care and 13.9 % of total costs) and outpatient
and primary health care visits (18.3 % of health costs and
7.9 % of total costs) (Fig. 2). The most relevant category of
direct non-health care cost was informal care, averaging
€21,447 (99.6 % of direct non-health care and 44.1 % of
total costs), with a special mention given to the cost re-
lated to main caregivers (75.8 % of direct non-health care
cost and 33.6 % of total costs). Social services only
accounted for 0.2 % of direct non-health care cost and
0.1 % of total costs, and non-health care transport rep-
resented 0.2 % of direct non-health costs and 0.1 % of
total costs respectively. Finally, sick leave accounted for
29 % of productivity loss and 3.7 % of total costs,
whereas early retirement accounted for 71 % of prod-
uctivity loss and 9.1 % of total costs.
The results differ significantly depending on whether
CF patients needed the help of a caregiver. A CF patient
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with caregiver help had a total average annual cost of
€76,271 (median €70,641), compared with €26,335 (median
€16,591) for a patient who did not require personal care.
Where a caregiver was present, implying higher sever-
ity patients, the most relevant cost category was informal
care with an average cost of €48,092 (63.1 % of total
costs). Direct medical and direct non-medical costs rep-
resented 31.5 and 63.1 % of total costs respectively. In
terms of direct medical cost categories, hospitalisations
ranked highest (26.2 % of direct medical costs, and 18.2
% of total costs), followed by medications (35.5 % of direct
medical costs and 24.7 % of total costs), and outpatient
and primary health care visits (19.1 % of direct medical
costs and 13.3 % of total costs). Social services only
accounted for 0.2 % of direct non-medical costs and 0.1 %
of total costs, whereas non-healthcare transport only
represented 0.2 % of the direct non-medical costs and a 0.7
% of total costs. Productivity loss accounted for 5.4 % of
total costs, with sick leave and early retirement separately
accounting for 29 and 71 % of indirect costs, and 3.7 and
9.1 % of total costs respectively.
For patients without a caregiver, direct medical and
direct non-medical costs represented 69.5 and 0.4 % of
total costs respectively, while indirect costs represented
30.1 % of total costs. The most important categories of
direct medical costs were medications (35.3 % of medical
costs and 24.7 % of total costs), acute hospitalizations
(26.2 % of medical costs and 18.2 % of total costs) and
outpatient visits (19.1 % of medical costs and 13.3 % of
total costs). Social health services and non-health care
transport accounted for 0.2 % and 0.15 % of total costs,
respectively. Sick leave and early retirement accounted
for 39.1 and 60.3 % of indirect costs and 12 and 18.2 %
of total costs, respectively.
Further analysis was conducted to explore the differ-
ences in costs between adults and children (Table 3).
Average total annual costs per adult and adolescent patient
were €44,583 (median €31,511) and €52,624 (€46,356)
respectively, of which direct and indirect costs comprised
72.1 (€32,140) and 27.9 % (€12,443) in the adult group,
with no indirect costs in the adolescent group. Direct
health care costs were much higher than direct non- health
care costs among adult patients (€26,439 vs. €5,701), com-
pared with the adolescent patients group, where the
opposite trend was observed (€15,268 vs. €37,355), indicat-
ing a much higher impact of informal care on total costs in
the adolescent group.
With regards to HRQOL of adult patients the EQ-5D
index score was 0.64 out of 1, and the EQ-5D visual
analogue scale score was 62.23 out of 100 (Table 1).
These scores are lower than the EQ-5D values for the
UK adult general population (0.93 and 86.84, respect-
ively) after controlling for age [32]. For caregivers, the
mean EQ-5D index and VAS scores were 0.836 and
80.85 respectively (Table 1), which are lower than in the
UK general population (0.91 and 86.56 respectively).
Among adult patients, the average Barthel index was
19.27 reflecting very low dependence, while the average
Zarit burden interview score burden was 29.03, indicat-
ing a moderate burden for caregivers (Table 1).
Discussion
In this study we have provided a descriptive rather than
quantitative analysis of total cost and HRQOL among
patients with CF. Among rare diseases, CF represents a
health problem with important societal impact in high-
income countries, including the UK [8, 9, 33]. The
Table 1 Sample characteristics of interviewed CF patients
(n = 74, SD in brackets)
Average age (years)
All patients 18.3 (15.1)




Is there a caregiver?
Yes 44.6 %
No 57.4 %
Average age of (principal) caregiver (years) 37.3 (11.6)
Average informal care hours per week (whole sample) 33.4 (52.9)
Average informal care hours per week (if there is a
caregiver)
74.8 (56.5)
Health Related Quality of Life (Visual Analog Scale) 62.23
(20.09)
Adult CF patients (n = 37)a
Visual Analog Scale score for general populationb 86.84
(14.41)
Main Caregivers for CF patients (n = 33)c 80.85
(14.68)
Visual Analog Scale score for general populationd 86.56
(13.79)
Health Related Quality of Life (EQ-5D index score)
Adult CF patients (n = 37)a 0.640
(0.264)
EQ-5D index score for general populationb 0.93 (0.15)
Main Caregivers for CF patients (n = 33)c 0.836
(0.155)
EQ-5D index score for general populationd 0.91 (0.16)
aOf the 37 adult patients, 30 filled the HRQoL questionnaire, out of which 25
patients filled the questionnaire themselves, 1 patient filled it using assistance
and 4 patients had the questionnaire filled in by someone else
bReflects general population social tariffs/utilities for the respective patients’
age group (i.e. 25–34)
cOf the 33 caregivers, 32 filled the HRQoL questionnaire
dReflects general population social tariffs/utilities for the respective caregivers’
age group (i.e. 35–44)
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incidence and prevalence of CF and its health and social
impact in terms of mortality, morbidity, economic cost
and quality of life justify the attention received from
health authorities and society. A recently published sys-
tematic review studying the socioeconomic impact of ten
rare diseases identified in total 29 costing studies related
to CF, four of which investigated aspects of CF manage-
ment in the UK mainly relating to direct health care costs
[17]. The first ever CF costing study in the UK
investigated the direct medical costs of patients served at
Table 2 Average annual costs per CF patient (2012, in €)
Total (n = 74) With carer (n = 33) Without carer (n = 41)
Mean ±SD Median Mean ±SD Median Mean ±SD Median
Direct Health Care Costs
Prescription medication 7,053.3 (4,737.1) 9,233.3 7,737.3 (4,619.3) 9,795.4 6,502.8 (4,815.3) 8,498.5
Tests 2,865.3 (4,463.7) 1,547.8 2,447.5 (4,124.2) 1,000.3 3,201.5 (4,742.9) 1,866.0
Outpatient & primary health care visits 3,823.3 (4,214.8) 2,513.7 4,224.1 (5,136.4) 2,526.5 3,500.7 (3,328.0) 2,454.2
Acute hospitalisation 6,759.1 (12,532.9) 802.8 9,208.4 (15,590.6) 3,211.4 4,787.7 (9,125.3) 0
Medical devices 287.8 (878.8) 98.7 271.2 (1,007.8) 98.7 301.3 (772.3) 98.7
Health care transportation 64.9 (506.4) 0 131.6 (755.7) 0 11.3 (67.8) 0
Subtotal 20,853.7 (21,336.6) 15,247.4 24,020.0 (26,057.9) 15,756.2 18,305.2 (16,513.4) 14,282.2
Direct Non Health Care Costs
Non-health care transportation 34.7 (55.6) 15.5 29.6 (32.1) 17.3 38.8 (69.2) 13.8
Social services 46.8 (298.4) 0 35 (200.9) 0 56.3 (360.6) 0
Caregiver time costs (informal care) 21,446.6 (34,034.7) 0 48,092.4 (36,345.7) 38,047.1 0 0 0
Main caregivers 16,323.2 (23,713.8) 0 36,603.5 (22,744.6) 34,831.9 0 0 0
Secondary caregivers 5,123.4 (14,701.3) 0 11,488.8 (20,435.9) 1,286.1 0 0 0
Subtotal 21,528.1 (34,020.5) 123.4 48,156.9 (36,336.1) 38,047.1 95.1 (366.5) 13.8
Total Direct Costs (Direct Health Care Costs & Direct
Non Health Care Costs)
42,381.8 (41,307.4) 28,254.6 72,176.9 (43,522.5) 65,806.9 18,400.4 (16,635.9) 14,370.3
Loss of Labour Productivity
Sick leave 1,805.2 (7,264.1) 0 132.4 (760.4) 0 3,151.7 (9,574.4) 0
Early retirement 4,416.3 (11,248.8) 0 3,961.3 (10,831.6) 0 4,782.6 (11,694.5) 0
Subtotal 6,221.6 (12,772.6) 0 4,093.7 (10,808.3) 0 7,934.3 (14,054.6) 0
TOTAL COSTS 48,603.4 (43,789.6) 34,883.3 76,270.6 (46,073.4) 70,640.8 26,334.6 (25,719.2) 16,591.4
Fig. 1 Breakdown of costs according to all CF patients, CF patients with carers, and CF patients without carers (2012, €)
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a regional adult CF centre [34]. To date however, this is
the first UK-based study attempting to quantify the total
(direct medical, direct non-medical and indirect) cost for
CF patients together with estimates of quality of life. Stud-
ies conducted in different settings prove testament to the
high costs associated with CF. For example, annual cost
per patient amounted to €41,468 in Germany [33],
whereas annual mean direct health care costs per patient
were shown to vary across countries. In Germany these
were found to range from €17,219 per patient per year, in-
creasing to €21,782 allowing for IV therapy [35]. In the
USA, one study showed average annual treatment costs
per patient to be $63,127 in 2006 (€50,299) [36], whereas
another study suggested a mean annual cost of $43,000
per CF patient in 2008 (€29,378) [15]; however the latter
is most likely to be an underestimate mainly because dir-
ect non-medical costs were not extensively investigated to
the same extent as in our study. In France the direct costs
were found to be €22,725 in 2003 [37], whereas in
Australia national registry data have indicated that the
presence of chronic infections increases cost of care by
70–164 % [16].
The present analysis highlights the importance of
studying the economic consequences of CF from a soci-
etal perspective and interpreting the results in an
international context. Our results provide insights into
the distribution of CF costs and their impact on national
health expenditure as well as patient and family income.
Beyond the average annual total cost of €48,603 (ranging
from €26,335 to €76,271 for patients without carers and
with carers, respectively), we found that informal care,
medication, acute hospitalisations, early retirement and
outpatient and primary health care visits represented the
highest expenditures.
The high contribution of informal care to the costs
identified in this study may have several explanations.
First, our methodology may have influenced our esti-
mates. In earlier studies, indirect costs included both job
loss and informal care costs. Recently published cost-of-
illness studies, however, use more precise classifications
of the items that contribute to societal costs. Second,
our study design excluded institutionalised patients from
the analysis and, therefore, the cost estimates produced
in this study are likely to be an under-estimate of the
total CF cost due to non-inclusion of institutionalisation
and long-term care costs.
HRQOL can be a useful indicator together with other
information sources such as incidence, prevalence, mor-
tality and costs to set priorities in health and measure
the effectiveness of health interventions on disease
Fig. 2 Average costs per CF patient broken down by type of cost (2012, €)
Table 3 Average annual costs (main groups only) for adult and adolescent CF patients, (2012, in €)
All patients (n = 74) Adult patients (n = 37) Adolescent patients (n = 37)
Mean ±SD Median Mean ±SD Median Mean ±SD Median
Direct Health Care Costs 20,853.7 (21,336.6) 15,247.4 26,439.3 (21,604.7) 21,944.0 15,268.2 (19,805.3) 9,599.8
Direct Non-Health Care Costs 21,528.1 (34,020.5) 123.4 5,700.8 (13,521.7) 31.1 37,355.4 (40,610.1) 24,313.1
Total Direct Costs 42,381.8 (41,307.4) 28,254.6 32,140.1 (29,596.5) 23,089.7 52,623.5 (48,666.5) 46,355.6
Indirect Costs 6,221.6 (12,772.6) 0 12,443.2 (15,850.7) 1,747.3 0 0 0
Total Costs 48,603.4 (43,789.6) 34,883.3 44,583.2 (38,557.5) 31,511.3 52,623.5 (48,666.5) 46,355.6
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management. Our analysis showed that the average EQ-
5D index score of adult CF patients was lower than in
the general population. Despite its relatively low preva-
lence, CF is characterized by a substantial economic bur-
den and patients with higher dependence on caregivers,
therefore reflecting a higher disability, are more likely to
incur higher productivity losses compared to people with
lower dependence. Although it would have been of great
interest to expand upon the notion of higher disease bur-
den being associated with higher cost by exploring the as-
sociation of decrements in EQ-5D scores with increases in
cost, this would not yield robust estimates because of the
relatively small number of patients with available EQ-5D
scores in the sample, giving rise to relative few degrees of
freedom and, therefore, decreasing the credibility of the
results. Instead, the existence or absence of a caregiver
was used as a proxy for disability, resulting in a larger
sample.
Our study is not without limitations. The first limita-
tion relates to sampling issues. Both the study sample
and the recruitment process may limit the external validity
of the study. However, other CF studies have used smaller
sample sizes due to the low disease prevalence and high
rates of participation refusal [35–38]. Although the sample
was almost evenly distributed between high- and low-
severity patients, we cannot guarantee the avoidance of
selection bias but this is common in most rare disease
studies involving small numbers of patients. There may
also be potential recall bias, given that patient-based data
were obtained by questionnaire. A second limitation
relates to the non-use of disease-specific HRQOL instru-
ments, such as the cystic fibrosis questionnaire (CFQ).
However, a recent systematic review of HRQOL instru-
ments used for rare diseases concluded that the EQ-5D-
5 L can be considered a cross-sectional valid generic health
outcome measure reflecting the progression of CF [39]. In
addition, we have used the Barthel Index and the Zarit
scale as proxies to measure disability and severity. Finally,
our study used cross-sectional data. An ideal study would
be a prospective longitudinal study of a CF cohort, but this
type of study was beyond our means and no such study
has been undertaken in CF.
Despite the limitations of cost-of-illness analysis stud-
ies, governments continue to encourage such research,
as the information emerging about the financial impact
of disease provides a useful input for program planning
and public policy design. This information complements
epidemiological data on population-level health prob-
lems. This study represents the most complete and real-
istic costing to date of the burden of CF performed in
the UK, a key strength being the use of a bottom-up
approach to costing. Additionally, estimating costs over
a one-year period has provided a more accurate picture
of the medium-term burden of CF.
Conclusion
By pursuing a bottom-up cost and HRQOL study, we
have shown that direct health care costs of CF are sub-
stantial, although other social costs, such as informal
care, are even higher proportionately, and that higher
disability, as reflected through the existence or absence
of a caregiver, is associated with significantly higher CF
social costs. Overall, CF represents a significant hidden
cost to society and this should be taken into account
when considering treatments and support programs for
CF patients and their caregivers. The data in this study
could form the basis for integrated and harmonised
approaches to periodically assess the future impact of
new public policies and interventions for rare diseases at
national and EU level.
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